Engineers Gate Manager LP Decreases Stake in BioMarin Pharmaceutical Inc. $BMRN

Engineers Gate Manager LP cut its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 58.4% during the second quarter, HoldingsChannel reports. The firm owned 181,647 shares of the biotechnology company’s stock after selling 255,213 shares during the quarter. Engineers Gate Manager LP’s holdings in BioMarin Pharmaceutical were worth $10,394,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Parkside Financial Bank & Trust grew its stake in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 187 shares in the last quarter. CIBC Private Wealth Group LLC lifted its holdings in BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after buying an additional 179 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in BioMarin Pharmaceutical during the 2nd quarter worth about $39,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $40,000. Finally, Parallel Advisors LLC boosted its position in shares of BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 295 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Stock Up 1.7%

BMRN opened at $65.51 on Friday. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The stock has a market capitalization of $12.68 billion, a P/E ratio of 177.05, a price-to-earnings-growth ratio of 0.46 and a beta of 0.24. The business’s 50-day simple moving average is $63.16 and its 200-day simple moving average is $58.45.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business’s revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BMRN shares. Bank of America cut their target price on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Morgan Stanley increased their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings raised shares of BioMarin Pharmaceutical from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, September 3rd. Oppenheimer boosted their price objective on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.17.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Positive Phase 3 VOXZOGO data: BioMarin reported that the CANOPY-HCH-3 study in children with hypochondroplasia achieved statistically significant improvements in annualized growth velocity, standing height, height Z-score and arm span. The results were published in NEJM Evidence and presented at the ESPE 2026 meeting, strengthening the case for expanding VOXZOGO’s addressable market. BioMarin Announces Positive Results of Phase 3 VOXZOGO Study
• Positive Sentiment: Regulatory expansion opportunity: BioMarin recently submitted a supplemental New Drug Application to the FDA seeking approval to use VOXZOGO in children with hypochondroplasia. Successful review could broaden the product’s commercial opportunity and support investor sentiment. BioMarin’s VOXZOGO Hits Phase 3 Growth Endpoint
• Neutral Sentiment: Investor conference updates: BioMarin presented at the Citigroup, Cantor Fitzgerald and Wells Fargo healthcare conferences. The transcripts provide additional management commentary on the pipeline and business outlook, but the supplied reports do not identify a new material financial or clinical announcement. Citigroup conference transcript
• Neutral Sentiment: Short-interest report appears unreliable: The report lists short interest at zero shares and a zero-day days-to-cover ratio, offering no meaningful bearish or bullish signal and likely reflecting a data-quality issue.
• Negative Sentiment: Analyst remains cautious: HC Wainwright reaffirmed a “neutral” rating and assigned a $60 price target, below the referenced $65.51 share price. That implies potential downside and signals skepticism about near-term valuation or execution. HC Wainwright analyst rating

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin’s marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.